Lv4
536 积分 2023-12-07 加入
Paclitaxel anti-cancer therapeutics: from discovery to clinical use
1天前
待确认
Mechanisms and interventions in relapsed/refractory extranodal natural killer/T-cell lymphoma
1个月前
已完结
Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs)
2个月前
已完结
Update on T-Cell Lymphoma Epidemiology
2个月前
已完结
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial
2个月前
已完结
Combined oral PI3Kδ inhibitor linperlisib and HDAC inhibitor chidamide in relapsed/refractory peripheral T-cell lymphoma: a multicenter phase 1 trial
2个月前
已完结
Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma
2个月前
已完结
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)
2个月前
已完结
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas
2个月前
已完结
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
2个月前
已完结
皖公网安备34019202002308
